IL197276A0 - Methods of inhibiting angiogenesis and treating angiogenesis associated diseases - Google Patents
Methods of inhibiting angiogenesis and treating angiogenesis associated diseasesInfo
- Publication number
- IL197276A0 IL197276A0 IL197276A IL19727609A IL197276A0 IL 197276 A0 IL197276 A0 IL 197276A0 IL 197276 A IL197276 A IL 197276A IL 19727609 A IL19727609 A IL 19727609A IL 197276 A0 IL197276 A0 IL 197276A0
- Authority
- IL
- Israel
- Prior art keywords
- angiogenesis
- methods
- associated diseases
- treating
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2006/034365 WO2008027055A1 (en) | 2006-08-31 | 2006-08-31 | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL197276A0 true IL197276A0 (en) | 2009-12-24 |
Family
ID=37763804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL197276A IL197276A0 (en) | 2006-08-31 | 2009-02-26 | Methods of inhibiting angiogenesis and treating angiogenesis associated diseases |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2056812A1 (pt) |
| JP (1) | JP2010502603A (pt) |
| CN (1) | CN101568332A (pt) |
| AU (1) | AU2006347740A1 (pt) |
| BR (1) | BRPI0622006A2 (pt) |
| CA (1) | CA2662140A1 (pt) |
| IL (1) | IL197276A0 (pt) |
| MX (1) | MX2009002054A (pt) |
| WO (1) | WO2008027055A1 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| US9675578B2 (en) | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP3417859A1 (en) | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| TW201012473A (en) * | 2008-09-22 | 2010-04-01 | Tty Biopharm Co Ltd | Composition of inhibiting pathological angiogenesis |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| CN102802658A (zh) * | 2009-12-21 | 2012-11-28 | 台湾东洋药品工业股份有限公司 | 白细胞衍生趋化因子2于肿瘤细胞内降低肝细胞生长因子受体的磷酸化相关的方法与组合物 |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| US20140228299A1 (en) * | 2011-09-20 | 2014-08-14 | National University Corporation Tokyo Medical And Dental University | Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases |
| PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス, エルエルシー | 肺がんを処置する方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス, エルエルシー | 膀胱がんを処置する方法 |
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| IL292439B2 (en) | 2019-10-28 | 2026-05-01 | Abraxis Bioscience Llc | Pharmaceutical preparations of albumin and rapamycin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1318401B1 (it) * | 2000-03-17 | 2003-08-25 | Indena Spa | Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono. |
| KR20140148502A (ko) * | 2002-12-09 | 2014-12-31 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| DK1585548T3 (en) * | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US6825236B2 (en) * | 2003-04-14 | 2004-11-30 | California Pacific Medical Center | Colchicine derivatives |
| ITMI20040164A1 (it) * | 2004-02-03 | 2004-05-03 | Indena Spa | Derivati di n.deacetiltiocolchicina loro uso e formulazioni farmaceutiche che li contengono |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
-
2006
- 2006-08-31 AU AU2006347740A patent/AU2006347740A1/en not_active Abandoned
- 2006-08-31 MX MX2009002054A patent/MX2009002054A/es not_active Application Discontinuation
- 2006-08-31 WO PCT/US2006/034365 patent/WO2008027055A1/en not_active Ceased
- 2006-08-31 CN CNA2006800561122A patent/CN101568332A/zh active Pending
- 2006-08-31 CA CA002662140A patent/CA2662140A1/en not_active Abandoned
- 2006-08-31 JP JP2009526583A patent/JP2010502603A/ja active Pending
- 2006-08-31 BR BRPI0622006-1A patent/BRPI0622006A2/pt not_active Application Discontinuation
- 2006-08-31 EP EP06802881A patent/EP2056812A1/en not_active Withdrawn
-
2009
- 2009-02-26 IL IL197276A patent/IL197276A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2056812A1 (en) | 2009-05-13 |
| MX2009002054A (es) | 2009-05-01 |
| JP2010502603A (ja) | 2010-01-28 |
| CN101568332A (zh) | 2009-10-28 |
| AU2006347740A1 (en) | 2008-03-06 |
| BRPI0622006A2 (pt) | 2011-12-20 |
| WO2008027055A1 (en) | 2008-03-06 |
| CA2662140A1 (en) | 2008-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291175A (en) | Compositions and methods for treating collagen-mediated diseases | |
| EP2032131A4 (en) | Methods of Treatment | |
| EP2019649A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING BODILUM DISORDER DISORDERS | |
| GB0610867D0 (en) | Treatment of pain | |
| IL202611A0 (en) | Methods of treating serotonin-mediated diseases and disorders | |
| IL197315A0 (en) | Treatment of cancer | |
| SI2056807T1 (sl) | Zdravljenje vnetnih bolezni | |
| IL193748A0 (en) | Treatment of pain | |
| ZA200905101B (en) | Diagosis and treatment of preeclampsia | |
| EP2049899A4 (en) | METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES | |
| IL198723A0 (en) | Methods and compositions for therapeutic treatment | |
| IL204728A0 (en) | Methods and compounds for treating retinol-related diseases | |
| PL2061501T3 (pl) | Sposób leczenia zaburzeń oddechowych | |
| PL2012814T3 (pl) | Sposoby leczenia chorób autoimmunologicznych | |
| GB0610350D0 (en) | prevention and/or treatment of neuodegenerative disorders | |
| ZA200808076B (en) | Methods for preventing and treating amyloidogenic diseases | |
| GB2445651B (en) | Well treatment products and methods of using them | |
| GB0610746D0 (en) | Method of treatment | |
| EP2164494A4 (en) | Methods of Treatment | |
| EP2019590A4 (en) | METHODS FOR TREATING DISEASES INVOLVING STRESS-RELATED CONDITIONS AND CONDITIONS | |
| IL192738A0 (en) | Compounds and methods for the treatment of cancer | |
| GB0610868D0 (en) | Treatment of pain | |
| GB0620695D0 (en) | Composition and methods for the treatment of nurdegenerative disease | |
| GB0618309D0 (en) | Compositions and methods for the treatment of disease | |
| GB0616450D0 (en) | Treatment of pain |